CD73
Alpha Lifetech can provide CD73 corresponding products, help each customer's research and development.
01
Introduction To CD73
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD73 protein is a common target in medicine.
CD73 is a membrane-bound extracellular 5-nucleotidase, also known as NT5E, produced by the NT5E gene, which catalyzes the dephosphorylation of nucleoside monophosphate to generate adenosine. CD73 is anchored to the cell membrane as a homodimer and can also be free extracellular. CD73 contains three domains, the N-terminal domain, the C-terminal domain, and the short helix connecting the N-terminal domain and the C-terminal domain. Through the short helix, there are two zinc ion binding sites on the N-terminal domain, and the C-terminal domain contains substrate binding sites and is anchored to the cell membrane by glycosylphosphatidylinositol (GPI).
Function of Target CD73
CD73 is an overexpressed enzyme in GB, acting through two main mechanisms: CD73 acts as an adhesion protein independent of enzyme activity, or through AMP catalysis to adenosine (ADO), inducing changes in tumor cells and tumor microenvironment cells (TME). Two important cell surface exoribosidases, CD39 and CD73, sequentially convert extracellular ATP to adenosine, playing a key role in remodeling the immunosuppressive TME. Meanwhile, CD39, CD73, and A2AR could serve as novel therapeutic targets for manipulating antitumor immunity. The adenosine generated by CD73 can bind to the adenosine receptors on the surface of immune cells (such as A 2 aR), thus inhibiting the activation and function of immune cells.
Gene Pathway of Target CD73
ATP and ADP were converted to AMP by the extracellular enzyme CD39 and further to adenosine (A) by CD73. Extracellular NAD + is converted to ADP-ribose and nicotinamide (Nam) by NAD + -glycohydrolase and ADP ribosyltransferase (ARTs). ADP ribose can be further cleaved by ADP ribose pyrophosphatase to form AMP and subsequently converted to adenosine by CD73. In addition, NAD + can also be degraded by the NAD + diphosphatase to produce nicotinamide mononucleotides. CD73 inhibits NLRP3 inflammasome complex activation, and CD73 represses GSDMD expression at the transcriptional level via Foxo1. Thus reducing the maturation of GSDMD, resulting in reduced pyroptosis in microglia.
Fig 1: CD73 Gene Pathway. (Reference source: Shi H, Dai H, Sun Q, Wang S, Chen Y. CD73, a significant protein in liver diseases. Front Med (Lausanne). 2023 Apr 12;10:1147782.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD73 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD73 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD73 protein products are also essential. Alpha Lifetech can provide CD73 corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64515 | 50ug,100ug,500ug | |
| ADT1417 | ADT1417-Mupadolimab Biosimilar-Anti NT5E/CD73 mAb- Research Grade | 100ug,1mg,5mg |
| ADT1678 | 100ug,1mg,5mg | |
Reference
[1] Xu S, Wang J, Zhong J, Shao M, Jiang J, Song J, Zhu W, Zhang F, Xu H, Xu G, Zhang Y, Ma X, Lyu F. CD73 alleviates GSDMD-mediated microglia pyroptosis in spinal cord injury through PI3K/AKT/Foxo1 signaling. Clin Transl Med. 2021 Jan;11(1):e269.
[2] Shi H, Dai H, Sun Q, Wang S, Chen Y. CD73, a significant protein in liver diseases. Front Med (Lausanne). 2023 Apr 12;10:1147782.
[3] Gelsleichter NE, Azambuja JH, Rubenich DS, Braganhol E. CD73 in glioblastoma: Where are we now and what are the future directions? Immunol Lett. 2023 Apr-May;256-257:20-27.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102